医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Extension and Advancement of a Peptide Discovery Program

2014年10月03日 PM04:28
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that one of the discovery programs initiated under the strategic alliance with Swiss-based Novartis has advanced into further optimization efforts, and will be extended and funded through an amendment to the original Strategic Alliance Agreement. PeptiDream identified macrocylic peptide candidates against an undisclosed target under the Macrocylic Peptide Drug Discovery Alliance, initiated in 2010 and extended in 2012. Candidates are undergoing optimization efforts in collaboration with Novartis, with PeptiDream using its PDPS system. The amendment provides additional research funding to cover additional PeptiDream resources focusing on the program’s optimization efforts and advancement.

[Comments from Patrick Reid, CSO, and Keiichi Masuya, COO, of PeptiDream Inc.]
“We are very excited with the program’s advancement. The additional funding will allow us to commit more resources toward the optimization efforts of this exciting program.”

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PerkinElmer Acquires Shanghai Spectrum Instruments Co., Ltd.
  • 珀金埃尔默收购上海光谱仪器有限公司
  • 据国际睡眠专家估计,全球有近10亿人罹患睡眠呼吸暂停
  • 世界中で10億人近くが睡眠時無呼吸症を患っていると世界の睡眠専門家らが推定
  • Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer’s Disease